FDA Calls Out Ferring For Sales Aid For Prostate Cancer Drug Firmagon That Cites Reduction In PSA Levels
This article was originally published in The Pink Sheet Daily
Executive Summary
Reducing rising PSA levels in advanced prostate cancer patients is not evidence of clinical benefit, FDA’s Office of Prescription Drug Promotion says.